Author of

• 11818

  +

  P2.13 - Poster Session 2 - SCLC (ID 201)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11819

    +

    P2.13-001 - Additive first-line chemotherapies improve progression-free survival for combined small cell lung cancer in a phase II randomized trial. (ID 317)

    09:30 - 09:30  |  Author(s): J. Zhang
    • Abstract

    Background
    We aimed to compare the efficacy of alternating etoposide-cisplatin and vinorelbine-cisplatin (EP-NP) versus etoposide-cisplatin (EP) only regimens for combined small cell carcinomas (C-SCLC) in a phase II randomized trial.

    Methods
    Eighty-two histologically proven C-SCLC patients were assigned to receive either the EP-NP regimen (Group A) or the EP regimen (Group B). Patients were followed up until either death occurred or exit study. The response rate (RR), progression-free survival (PFS), overall survival (OS), and toxicity were recorded and analyzed.

    Results
    The overall 1-year survival rate was 40% and the median OS and median PFS was 11.47 and 6.08 months, respectively. Additionally, 1-year PFS in Group A was significantly better than that in Group B (18% vs. 3%, p = 0.041). There were 18 (42.9%) Partial response (PR), 19 (45.2%) Stable disease (SD), and 5 Progressive disease (PD) in Group A and 13 (32.5%) PR, 25 (62.5%) SD, and 2 PD cases in Group B. The median survival time was 11.47 months, 1-year and 2-year overall survival rates were 43% and 13% in Group A and 38% and 10% in Group B, respectively. No significant survival differences were found between two groups (p = 0.866). Multivariate analysis showed that chemo-response was predictive of longer survival (hazard ratio: 2.635; 95% CI: 1.681-4.131; p < 0.001, respectively).

    Conclusion
    The addition of NP to EP regimen for C-SCLC improved progression-free survival as compared to EP-only administration.